Screener
Mineralys Therapeutics, Inc. MLYS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 14,718 | 15,113 |
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 82,454,950 and 81,536,557 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 8 | 8 |
| Additional paid-in capital | 1,134,644 | 1,103,854 |
| Accumulated deficit | (496,508) | (457,169) |
| Total stockholders’ equity | 638,144 | 646,693 |
| Total liabilities and stockholders’ equity | $652,862 | $661,806 |
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s total equity?
- Mineralys Therapeutics, Inc. (MLYS) reported total equity of $638.14M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s total equity changed year-over-year?
- Mineralys Therapeutics, Inc.'s total equity increased by 86.8% year-over-year, from $341.56M to $638.14M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s total equity?
- Over 4 years (2021 to 2025), Mineralys Therapeutics, Inc.'s total equity has grown at a 130.5% compound annual growth rate (CAGR), from -$22.93M to $646.69M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Mineralys Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude